Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR plus ) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
CANCER RESEARCH(2022)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined